LOGIN  |  REGISTER
Recursion

Boston Scientific to Participate in Stifel's 2023 Healthcare Conference

November 01, 2023 | Last Trade: US$94.88 1.07 -1.12

MARLBOROUGH, Mass., Nov. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023.

Dan Brennan, executive vice president and chief financial officer, and Lauren Tengler, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. A live webcast of the session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

CONTACTS:
Media:
Katie Schur
508-683-5574 (office)
Media Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations:
Lauren Tengler
508-683-4479 (office)
Investor Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page